Express Scripts Champions $1 per Pill Access to an Alternative for Daraprim

ST. LOUIS, Dec. 1, 2015 /PRNewswire/ -- Express Scripts (NASDAQ: ESRX) today announced it will partner with Imprimis Pharmaceuticals (NASDAQ: IMMY) to drive access to a low-cost alternative to Daraprim (pyrimethamine), a drug for the treatment of toxoplasmosis that has been recently priced out of reach for people with HIV, pregnant women and others with weakened immune systems.



RSS - Express-Scripts.com